OGEN oragenics.com Total Asset Value of Company

The price action of Oragenics, Inc. (OGEN) securities reflects the dynamics of total assets, which currently stand at 3.81. Oragenics, Inc. (OGEN) is mitigating technological threats by developing treatments for infections and head injuries. The business model relies on fixed R&D costs followed by the sale of licenses, which eliminates the need for capital expenditures. High authority within the scientific community confirms the brand's competencies, although the market currently prices the asset as a venture play.

When assessing the long-term sustainability of Oragenics, Inc. (OGEN), an investor must analyze the company's aggregate resources calculated reverse-engineered through return on assets (ROA), where the level of total assets demonstrates the business's ability to withstand external shocks through a balance of equity and liabilities, which is critically important when scaling software robotization and deploying automated molecule screening stations.